383 related articles for article (PubMed ID: 37767463)
1. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
Zhang Z; Zhang R; Li D
Biologics; 2023; 17():113-128. PubMed ID: 37767463
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
3. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
Sakach E; O'Regan R; Meisel J; Li X
Clin Breast Cancer; 2021 Dec; 21(6):509-520. PubMed ID: 34629314
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Shao F; Sun H; Deng CX
Oncotarget; 2017 Sep; 8(42):73329-73344. PubMed ID: 29069872
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
7. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
8. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N; Owusu E; Rivera G; Bandyopadhyay D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
[TBL] [Abstract][Full Text] [Related]
11. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract][Full Text] [Related]
12. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
[TBL] [Abstract][Full Text] [Related]
14. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
15. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness.
Lee KL; Kuo YC; Ho YS; Huang YH
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31505803
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
17. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
18. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer.
Varshini MS; Krishnamurthy PT; Reddy RA; Wadhwani A; Chandrashekar VM
Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38385495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]